



VIA SEDAR

May 29th, 2020
Financial Reporting Department
British Columbia Securities Commission

Dear Sirs/Mesdames:

Re: Interim M&A – SEDAR Project Number: 03021108

Please be advised that we are hereby re-filing BioMark Diagnostics Inc's management's discussion & analysis (MD&A) for the interim period ended December 31, 2019, following a continuous disclosure review by the British Columbia Securities Commission ("BCSC") and replaces the version previously filed on SEDAR on February 25th, 2020. Among other changes, the amended and restated interim MD&A has been revised:

- To identify forward-looking information or state the material factors and assumptions used to develop forward-looking information and describe the Company's policy for updating forward-looking information as required by Section 4A.3 and Section 5.8 of NI 51-102
- To provide results of operations for the quarter ended, and the cumulative year-to-date period with the comparative information to the same period in the previous year
- To provide a comparison of the intended use of proceeds as disclosed in the company's news releases and the actual use of proceeds, and to disclose the relevant material contract
- To discuss the factors that caused significant variations from the previous quarter, especially the company's policy in compliance with IFRS 15 for revenue recognition related to significant increase in revenue
- To explain the discrepancy on stock-based compensation between Interim Financial Statement and the Interim MD&A
- To better explain how the COVID-19 pandemic will impact the company's business, update the overall performance and risk factor sections for future filing and ensure all relevant risks are disclosed and tailored to the Company's specific situation

For further information, please do not hesitate to communicate with the undersigned.

Yours truly,

/s/ Guoyu Huang
GUOYU HUANG
Interim Chief Financial Officer
BioMark Diagnostics Inc.